TNSN01114A1 - Derives d'imidazole nouveaux et compositions les contenant - Google Patents

Derives d'imidazole nouveaux et compositions les contenant

Info

Publication number: TNSN01114A1
Authority: TN; Tunisia
Prior art keywords: compositions containing; imidazole derivatives; new imidazole; compounds; new
Prior art date: 2000-07-31

Application number

TNTNSN01114A

Other languages

English (en)

French (fr)

Inventor

Kirk Ahlijanian Michael

Blair Cooper Christopher

John Helal Christopher

Lau Lit-Fui

Samuel Menniti Frank

Allen Sanner Mark

Ann Seymour Patricia

Villatobos Anabella

Original Assignee

Pfizer Prod Inc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2000-07-31

Filing date

2001-07-30

Publication date

2005-11-10

2001-07-30 Application filed by Pfizer Prod Inc filed Critical Pfizer Prod Inc

2005-11-10 Publication of TNSN01114A1 publication Critical patent/TNSN01114A1/fr

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/16—Masculine contraceptives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/14—Drugs for dermatological disorders for baldness or alopecia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/06—Anabolic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
- C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
- C07D233/66—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D233/88—Nitrogen atoms, e.g. allantoin
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
- C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
- C07D233/66—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D233/90—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Life Sciences & Earth Sciences (AREA)
Veterinary Medicine (AREA)
General Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Chemical Kinetics & Catalysis (AREA)
Pharmacology & Pharmacy (AREA)
Public Health (AREA)
Animal Behavior & Ethology (AREA)
General Health & Medical Sciences (AREA)
Neurology (AREA)
Diabetes (AREA)
Neurosurgery (AREA)
Biomedical Technology (AREA)
Endocrinology (AREA)
Hematology (AREA)
Immunology (AREA)
Reproductive Health (AREA)
Obesity (AREA)
Orthopedic Medicine & Surgery (AREA)
Physical Education & Sports Medicine (AREA)
Psychology (AREA)
Pain & Pain Management (AREA)
Cardiology (AREA)
Hospice & Palliative Care (AREA)
Urology & Nephrology (AREA)
Heart & Thoracic Surgery (AREA)
Emergency Medicine (AREA)
Oncology (AREA)
Communicable Diseases (AREA)
Dermatology (AREA)
Gynecology & Obstetrics (AREA)
Pregnancy & Childbirth (AREA)
Psychiatry (AREA)
Child & Adolescent Psychology (AREA)

TNTNSN01114A 2000-07-31 2001-07-30 Derives d'imidazole nouveaux et compositions les contenant TNSN01114A1 (fr)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
US22172400P	2000-07-31	2000-07-31

Publications (1)

Publication Number	Publication Date
TNSN01114A1 true TNSN01114A1 (fr)	2005-11-10

Family

ID=22829075

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
TNTNSN01114A TNSN01114A1 (fr)	2000-07-31	2001-07-30	Derives d'imidazole nouveaux et compositions les contenant

Country Status (35)

Country	Link
EP (1)	EP1305295A1 (es)
JP (2)	JP4166084B2 (es)
KR (1)	KR20030019644A (es)
CN (1)	CN1444567A (es)
AP (1)	AP2001002232A0 (es)
AR (1)	AR032629A1 (es)
AU (1)	AU2001270944A1 (es)
BG (1)	BG107469A (es)
BR (1)	BR0112862A (es)
CA (1)	CA2418115A1 (es)
CR (1)	CR6861A (es)
CZ (1)	CZ2003225A3 (es)
DO (1)	DOP2001000220A (es)
EA (1)	EA200300097A1 (es)
EC (1)	ECSP034445A (es)
EE (1)	EE200300049A (es)
GT (1)	GT200100147A (es)
HR (1)	HRP20030048A2 (es)
HU (1)	HUP0303069A3 (es)
IL (1)	IL153787A0 (es)
IS (1)	IS6662A (es)
MA (1)	MA26932A1 (es)
MX (1)	MXPA03000939A (es)
NO (1)	NO20030472L (es)
NZ (1)	NZ523272A (es)
OA (1)	OA12345A (es)
PA (1)	PA8523701A1 (es)
PE (1)	PE20020337A1 (es)
PL (1)	PL365134A1 (es)
SK (1)	SK1042003A3 (es)
SV (1)	SV2002000571A (es)
TN (1)	TNSN01114A1 (es)
UY (1)	UY26862A1 (es)
WO (1)	WO2002010141A1 (es)
ZA (1)	ZA200300819B (es)

Families Citing this family (46)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
HK1042251B (en)	1999-01-13	2012-07-20	Bayer Healthcare Llc	Omega-carboxy aryl substituted diphenyl ureas as p38 kinase inhibitors
ME00275B (me)	1999-01-13	2011-02-10	Bayer Corp	ω-KARBOKSIARIL SUPSTITUISANI DIFENIL KARBAMIDI KAO INHIBITORI RAF KINAZE
US8124630B2 (en)	1999-01-13	2012-02-28	Bayer Healthcare Llc	ω-carboxyaryl substituted diphenyl ureas as raf kinase inhibitors
AU2003209119A1 (en)	2002-02-11	2003-09-04	Bayer Pharmaceuticals Corporation	Pyridine, quinoline, and isoquinoline n-oxides as kinase inhibitors
EP1478358B1 (en)	2002-02-11	2013-07-03	Bayer HealthCare LLC	Sorafenib tosylate for the treatment of diseases characterized by abnormal angiogenesis
WO2003106455A1 (en)	2002-06-14	2003-12-24	Applied Research Systems Ars Holding N.V.	Azole methylidene cyanide derivatives and their use as protein kinase modulators
US7141561B2 (en)	2002-07-25	2006-11-28	Sanofi-Aventis Deutschland Gmbh	Substituted diaryl heterocycles, process for their preparation and their use as medicaments
DE10233817A1 (de) *	2002-07-25	2004-02-12	Aventis Pharma Deutschland Gmbh	Substituierte Diarylheterocyclen, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
GB0308968D0 (en) *	2003-04-17	2003-05-28	Glaxo Group Ltd	Medicaments
PT1626714E (pt)	2003-05-20	2007-08-24	Bayer Pharmaceuticals Corp	Diarilureias para doenças mediadas por pdgfr
DE602004010407T2 (de)	2003-07-23	2008-10-16	Bayer Pharmaceuticals Corp., West Haven	Fluorsubstituierter omega-carboxyaryldiphenylharnstoff zur behandlung und prävention von krankheiten und leiden
US7342118B2 (en)	2004-03-23	2008-03-11	Pfizer Inc	Imidazole compounds for the treatment of neurodegenerative disorders
ATE517885T1 (de)	2004-04-30	2011-08-15	Bayer Healthcare Llc	Substituierte pyrazolyl-harnstoff-derivate zur behandlung von krebs
RU2399614C2 (ru)	2004-09-21	2010-09-20	Астеллас Фарма Инк.	Аминоспиртовые производные
WO2006117212A2 (en)	2005-05-04	2006-11-09	Develogen Aktiengesellschaft	Use of gsk-3 inhibitors for preventing and treating pancreatic autoimmune disorders
EP2258358A3 (en)	2005-08-26	2011-09-07	Braincells, Inc.	Neurogenesis with acetylcholinesterase inhibitor
JP2009506069A (ja)	2005-08-26	2009-02-12	ブレインセルス，インコーポレイティド	ムスカリン性受容体調節による神経発生
RS20080139A (sr) *	2005-09-22	2009-05-06	Pfizer Products Inc.,	Jedinjenja imidazola za lečenje neuroloških poremećaja
JP2009512711A (ja)	2005-10-21	2009-03-26	ブレインセルス，インコーポレイティド	Ｐｄｅ阻害による神経新生の調節
JP2009513672A (ja)	2005-10-31	2009-04-02	ブレインセルス，インコーポレイティド	神経発生のｇａｂａ受容体媒介調節
KR20080091369A (ko)	2006-01-18	2008-10-10	암젠 인크	단백질 키나제 ｂ（ｐｋｂ） 억제제로서 티아졸 화합물
US20100216734A1 (en)	2006-03-08	2010-08-26	Braincells, Inc.	Modulation of neurogenesis by nootropic agents
AU2007249399A1 (en)	2006-05-09	2007-11-22	Braincells, Inc.	Neurogenesis by modulating angiotensin
MX2009004140A (es) *	2006-10-21	2009-07-10	Abbott Gmbh & Co Kg	Compuestos heterociclicos y su uso como inhibidores de la glucogeno sintasa quinasa 3.
WO2009017453A1 (en) *	2007-07-30	2009-02-05	Astrazeneca Ab	New therapeutic combination of an antipsychotic and a gsk3 inhibitor 958
MX2010011663A (es) *	2008-04-24	2011-01-21	Abbott Gmbh & Co Kg	Derivados de 1-(7-hexahidropirrolo [3,4-c] pirrol-2 (1h)-il) quinolin-3-il)-(pirazin-2-il) urea y compuestos relacionados como glicogeno sintasa quinasa 3 (gsk-3).
WO2010099217A1 (en)	2009-02-25	2010-09-02	Braincells, Inc.	Modulation of neurogenesis using d-cycloserine combinations
WO2012041814A1 (en)	2010-09-27	2012-04-05	Abbott Gmbh & Co. Kg	Heterocyclic compounds and their use as glycogen synthase kinase-3 inhibitors
US9090592B2 (en)	2010-12-30	2015-07-28	AbbVie Deutschland GmbH & Co. KG	Heterocyclic compounds and their use as glycogen synthase kinase-3 inhibitors
PT2928474T (pt)	2012-12-07	2019-01-30	Chemocentryx Inc	Diazol lactamas
DK2935227T3 (en) *	2012-12-21	2017-12-04	Chemocentryx Inc	DIAZOLAMIDES AS CCR1 RECEPTOR ANTAGONISTS
JP6616190B2 (ja) *	2014-02-07	2019-12-04	国立大学法人東京医科歯科大学	筋形成促進剤、筋萎縮抑制剤、医薬組成物及びｔａｚ活性化剤
PL3344273T3 (pl)	2015-08-31	2020-06-01	Nutramax Laboratories, Inc.	Kompozycje zawierające magnolię, korkowiec, teaninę i/lub białko serwatkowe
GB201605126D0 (en)	2016-03-24	2016-05-11	Univ Nottingham	Inhibitors and their uses
CN109310677A (zh)	2016-04-07	2019-02-05	凯莫森特里克斯股份有限公司	通过联合施用ccr1拮抗剂与pd-1抑制剂或pd-l1拮抗剂降低肿瘤负荷
CN111018840B (zh) *	2017-10-25	2022-09-09	西南大学	3-咪唑取代的靛红唑醇类化合物及其制备方法和医药应用
JP7482122B2 (ja) *	2018-07-03	2024-05-13	アイエフエムデューインコーポレイテッド	Ｓｔｉｎｇ活性に関連する状態を治療するための化合物および組成物
US20220133740A1 (en)	2019-02-08	2022-05-05	Frequency Therapeutics, Inc.	Valproic acid compounds and wnt agonists for treating ear disorders
GB201908424D0 (en) *	2019-06-12	2019-07-24	Imp College Innovations Ltd	Novel compounds
US11884634B2 (en)	2019-08-09	2024-01-30	Pfizer Inc.	Compositions of solid forms of (S)-2-(((S)-6,8-difluoro-1,2,3,4- tetrahydronaphthalen-2-yl)amino)-N-(1-(2-methyl-1-(neopentylamino)propan-2-yl)-1H-imidazol-4-yl)pentanamide
US10590087B1 (en)	2019-08-09	2020-03-17	Pfizer Inc.	Solid state forms of (S)-2-(((S)-6,8-difluoro-1,2,3,4-tetrahydronaphthalen-2-yl)amino)-N-(1-(2-methyl-1-(neopentylamino)propan-2-yl)-1H-imidazol-4-yl)pentanamide and uses thereof
EP4229037A2 (en) *	2020-10-16	2023-08-23	CeMM - Forschungszentrum für Molekulare Medizin GmbH	Heterocyclic cullin ring ubiquitin ligase compounds and uses thereof
CN112250636A (zh) *	2020-11-09	2021-01-22	广西科技大学	5-氨基咪唑类化合物及其合成方法
JP2024519215A (ja)	2021-05-07	2024-05-09	カイメラセラピューティクス，インコーポレイテッド	Ｃｄｋ２分解剤およびそれらの使用
EP4396159A1 (en)	2021-09-01	2024-07-10	Springworks Therapeutics, Inc.	Synthesis of nirogacestat
US11504354B1 (en)	2021-09-08	2022-11-22	SpringWorks Therapeutics Inc..	Chlorinated tetralin compounds and pharmaceutical compositions

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US5401851A (en) *	1992-06-03	1995-03-28	Eli Lilly And Company	Angiotensin II antagonists
US5760246A (en) *	1996-12-17	1998-06-02	Biller; Scott A.	Conformationally restricted aromatic inhibitors of microsomal triglyceride transfer protein and method
ZA987383B (en) *	1997-08-19	2000-02-17	Lilly Co Eli	Treatment of congestive heart failure with growth hormone secretagogues.
ZA987385B (en) *	1997-08-19	2000-04-18	Lilly Co Eli	Growth hormone secretagogues.
JP4533534B2 (ja) *	1998-06-19	2010-09-01	ノバルティスバクシンズアンドダイアグノスティックス，インコーポレーテッド	グリコーゲンシンターゼキナーゼ３のインヒビター
WO2000021550A2 (en) *	1998-10-13	2000-04-20	President And Fellows Of Harvard College	Methods and compositions for treating neurodegenerative diseases
CO5160260A1 (es) *	1999-02-19	2002-05-30	Lilly Co Eli	Secretagogos de la hormona del crecimiento derivados de imi- dazol 1,4- substituido
DE69912808T2 (de) *	1999-12-08	2004-09-30	Centre National De La Recherche Scientifique (C.N.R.S.)	Verwendung von Hymenialdisin und dessen Derivaten zur Herstellung therapeutischer Mittel

2001
- 2001-07-23 GT GT200100147A patent/GT200100147A/es unknown
- 2001-07-25 JP JP2002516273A patent/JP4166084B2/ja not_active Expired - Fee Related
- 2001-07-25 OA OA1200300017A patent/OA12345A/en unknown
- 2001-07-25 KR KR10-2003-7001455A patent/KR20030019644A/ko not_active Ceased
- 2001-07-25 EP EP01949833A patent/EP1305295A1/en not_active Withdrawn
- 2001-07-25 EA EA200300097A patent/EA200300097A1/ru unknown
- 2001-07-25 PL PL01365134A patent/PL365134A1/xx not_active Application Discontinuation
- 2001-07-25 WO PCT/IB2001/001335 patent/WO2002010141A1/en not_active Ceased
- 2001-07-25 PE PE2001000752A patent/PE20020337A1/es not_active Application Discontinuation
- 2001-07-25 CN CN01813397A patent/CN1444567A/zh active Pending
- 2001-07-25 CA CA002418115A patent/CA2418115A1/en not_active Abandoned
- 2001-07-25 MX MXPA03000939A patent/MXPA03000939A/es active IP Right Grant
- 2001-07-25 SK SK104-2003A patent/SK1042003A3/sk not_active Application Discontinuation
- 2001-07-25 IL IL15378701A patent/IL153787A0/xx unknown
- 2001-07-25 EE EEP200300049A patent/EE200300049A/xx unknown
- 2001-07-25 NZ NZ523272A patent/NZ523272A/en unknown
- 2001-07-25 HU HU0303069A patent/HUP0303069A3/hu unknown
- 2001-07-25 CZ CZ2003225A patent/CZ2003225A3/cs unknown
- 2001-07-25 HR HR20030048A patent/HRP20030048A2/hr not_active Application Discontinuation
- 2001-07-25 BR BR0112862-0A patent/BR0112862A/pt not_active IP Right Cessation
- 2001-07-25 AU AU2001270944A patent/AU2001270944A1/en not_active Abandoned
- 2001-07-26 AP APAP/P/2001/002232A patent/AP2001002232A0/en unknown
- 2001-07-27 SV SV2001000571A patent/SV2002000571A/es not_active Application Discontinuation
- 2001-07-27 DO DO2001000220A patent/DOP2001000220A/es unknown
- 2001-07-30 AR ARP010103637A patent/AR032629A1/es unknown
- 2001-07-30 UY UY26862A patent/UY26862A1/es not_active Application Discontinuation
- 2001-07-30 TN TNTNSN01114A patent/TNSN01114A1/fr unknown
- 2001-07-31 PA PA20018523701A patent/PA8523701A1/es unknown
2002
- 2002-12-18 CR CR6861A patent/CR6861A/es not_active Application Discontinuation
- 2002-12-19 IS IS6662A patent/IS6662A/is unknown
2003
- 2003-01-16 BG BG107469A patent/BG107469A/bg unknown
- 2003-01-20 MA MA27004A patent/MA26932A1/fr unknown
- 2003-01-22 EC EC2003004445A patent/ECSP034445A/es unknown
- 2003-01-29 ZA ZA200300819A patent/ZA200300819B/en unknown
- 2003-01-30 NO NO20030472A patent/NO20030472L/no not_active Application Discontinuation
2008
- 2008-05-19 JP JP2008131176A patent/JP2008255123A/ja not_active Withdrawn

Also Published As

Publication number	Publication date
EA200300097A1 (ru)	2003-06-26
NO20030472L (no)	2003-03-27
BG107469A (bg)	2003-09-30
AP2001002232A0 (en)	2001-09-30
PA8523701A1 (es)	2002-04-25
HRP20030048A2 (en)	2003-04-30
NO20030472D0 (no)	2003-01-30
JP2004505111A (ja)	2004-02-19
CR6861A (es)	2004-03-11
NZ523272A (en)	2004-08-27
MXPA03000939A (es)	2003-06-24
PL365134A1 (en)	2004-12-27
WO2002010141A1 (en)	2002-02-07
PE20020337A1 (es)	2002-05-08
OA12345A (en)	2004-04-13
BR0112862A (pt)	2003-07-01
JP4166084B2 (ja)	2008-10-15
KR20030019644A (ko)	2003-03-06
AR032629A1 (es)	2003-11-19
SK1042003A3 (en)	2004-05-04
ZA200300819B (en)	2004-04-20
IS6662A (is)	2002-12-19
IL153787A0 (en)	2003-07-31
GT200100147A (es)	2002-06-25
DOP2001000220A (es)	2002-05-15
ECSP034445A (es)	2003-03-10
CN1444567A (zh)	2003-09-24
CZ2003225A3 (cs)	2004-02-18
JP2008255123A (ja)	2008-10-23
EE200300049A (et)	2004-10-15
EP1305295A1 (en)	2003-05-02
MA26932A1 (fr)	2004-12-20
AU2001270944A1 (en)	2002-02-13
CA2418115A1 (en)	2002-02-07
UY26862A1 (es)	2002-02-28
SV2002000571A (es)	2002-10-24
HUP0303069A2 (hu)	2004-03-01
HUP0303069A3 (en)	2004-04-28

Publication	Publication Date	Title
TNSN01114A1 (fr)	2005-11-10	Derives d'imidazole nouveaux et compositions les contenant
TNSN01095A1 (fr)	2005-11-10	DERIVES DE PYRROLO [2,3-d] PYRIMIDINE NOUVEAUX ET COMPOSITIONS LES CONTENANT
TNSN01048A1 (fr)	2005-11-10	Acides malonamiques et leurs derives, et compositions les contenant
TNSN01132A1 (fr)	2005-11-10	Derives de pyrazole nouveaux et compositions les contenant.
TNSN02014A1 (fr)	2005-12-23	Composes nouveaux agonistes de ppar et compositions les contenant
TNSN00036A1 (fr)	2005-11-10	Acides oxamiques nouveaux, procede pour leur preparation et compositions pharmaceutiques les contenant.
TNSN98084A1 (fr)	2005-03-15	Derives de macrolides substitues en position c-4
TNSN02008A1 (fr)	2005-12-23	Derives d'acides isophtalique nouveaux inhibiteurs de mmp, et compositions les contenant
TNSN98017A1 (fr)	2005-03-15	Derives de sulfonyluree, procede pour leur preparation et compositions pharmaceutiques les contenant.
TNSN02015A1 (fr)	2005-12-23	Composes nouveaux antagonistes de ppar, et compositions les contenant
TNSN02010A1 (fr)	2005-12-23	Derives de pyrimidine nouveaux inhibiteurs de mmp, et compositions les contenant
TNSN99125A1 (fr)	2005-11-10	Pyrrolo(2,3-d) pyrimidines nouvelles, procede pour leur preparation et compositions pharmaceutiques les contenant
TNSN01047A1 (fr)	2005-11-10	Procede pour la preparation de derives de piperazine nouveaux
TNSN99155A1 (fr)	2005-11-10	1-aryl-3-arylmethyl-1,8-naphtyridine-4(1h)-ones nouvelles, procede pour leur preparation et compositions pharmaceutiques les contenant
TNSN97198A1 (fr)	2005-03-15	Derives de 6-phenylpyridyl-2- amine et compositions pharmaceutiques les contenant
TNSN98238A1 (fr)	2005-03-15	Macrolides nouveaux
TNSN99252A1 (fr)	2005-11-10	Composes nouveaux modulateurs de chimiokine ccr5 et compositions pharmaceutiques les contenant.
TNSN01019A1 (fr)	2005-11-10	Pyrimidinecarboxamides utiles comme inhibiteurs d'iso-ezymes pde4, et compositions les contenant
TNSN02032A1 (fr)	2005-12-23	Derives de glutaramide a substituant n-phenpropylcyclopentyle nouveaux, et compositions les contenant.
TNSN02011A1 (fr)	2005-12-23	Derives de pyrimidine bicycliques nouveaux, inhibiteurs de mmp, et compositions les contenant
TNSN01020A1 (fr)	2005-11-10	Derives heterocycliques benzocondenses de nicotinamide, et compositions les contenant
TNSN99106A1 (fr)	2005-11-10	Derives d'isothiazole nouveaux, procede pour leur preparation et compositions pharmaceutiques les contenant.
TNSN02037A1 (fr)	2005-12-23	Sulfonylpyridazinones nouvelles inhibitrices d'aldose reductase et compositions les contenant
TNSN00239A1 (fr)	2005-11-10	DERIVES DE PYRROLO [2,3-d] PYRIMIDINE NOUVEAUX, ET COMPOSITIONS LES CONTENANT
TNSN98082A1 (fr)	2005-03-15	DERIVES SUBSTITUES EN C - 4 DE 9 - DESOXO - 9a - aza - 9a HOMOERYTHROMYCINE A.